BioSpace News Archive

CSO Dr. Kristin Comella will present clinical data demonstrating safety and efficacy of its proprietary Adipocell therapy in treating degenerative disc disease.

Acacia is pleased to announce it has received its License to Operate: Manufactured Food Establishment certificate issued on November 8, 2017 by the Colorado Department of Public Health and Environment.

Procedures were completed in the USA and Europe [28-November-2017] PRINCETON, New Jersey and OR AKIVA, Israel, November 28, 2017 /PRNewswire/ -- Regentis Biomaterials [http://www.regentis.co.il ] announced today the start of its Phase III pivotal clinical trial of GelrinC for the treatment of focal knee cartilage defects with successful surgery

According to market research by the International Agency for Research on Cancer (2), the global CINV market will reach a valuation of US$1.88 bn by 2020, rising from its 2013 valuation of US$1.28 bn.

he company believes that current market conditions are not conducive for an offering on terms that would be in the best interests of its stockholders.

The unaudited financial statements, Management’s Discussion and Analysis, and the CEO & CFO certifications for the period ended September 30, 2017 are available on www.SEDAR.com.

The LifeVest is worn by patients at risk of sudden cardiac death (SCD), providing protection during their changing condition and while permanent SCD risk has not been established.

BioIVT now provides a wide range of skin products for safety, efficacy and toxicity testing.

After 24 weeks of treatment, Myrcludex demonstrated excellent safety profile with no drug-related SAEs or treatment discontinuations due to the study drug.

The shares of common stock issued under the Agreement will be “restricted securities” as defined by the Securities Act of 1933, as amended.